Phosphodiesterase type 5 inhibitor therapy: Identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction

Current Medical Research and Opinion

Volumn 23, Issue 12, 2007, Pages 3189-3198

  Axilrod, Andrew C ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Comorbidities; Erectile dysfunction; Erection; First dose success; PDE5 inhibitors; Vardenafil

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

AGING; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; ISCHEMIC OPTIC NEUROPATHY; MEDLINE; POPULATION; PREVALENCE; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; TREATMENT DURATION; TREATMENT WITHDRAWAL;

CARDIOVASCULAR DISEASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ERECTILE DYSFUNCTION; HUMANS; MALE; PATIENT SELECTION; PHOSPHODIESTERASE INHIBITORS; TREATMENT OUTCOME;

EID: 37749013595     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242656     Document Type: Review

References (64)

1. Jardin A, Wagner G, Khoury S. Recommendations of the first international consultation on erectile dysfunction. In: Jardin A, Wagner G, Khoury S, Giuliano F, eds. Erectile Dysfunction. Plymouth, UK: Health Publications, 2000
2. Saigal CS, Wessells H, Pace J, et al. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006;166:207-12
3. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995;22:699-709
4. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
5. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-6
6. Kaiser FE, Viosca SP, Morley JE, et al. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc 1988;36: 511-19
7. Maatman TJ, Montague DK, Martin LM. Erectile dysfunction in men with diabetes mellitus. Urology 1987;29:589-92
8. Rosen RC, Fisher WA, Eardley I, et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20:607-17
9. National Institutes of Health Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90
10. American Urological Association 2005. Management of erectile dysfunction: American Urological Association (AUA) Education and Research, Inc [online]. Available from http://www.auanet. org/ [Last accessed 07 August 2007]
11. Kolodny L. Erectile dysfunction and vascular disease. What is the connection? Postgrad Med 2003;114:30-4
12. Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005;96:313-21
13. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 2006;3:28-36
14. De Angelis L, Marfella MA, Siniscalchi M, et al. Erectile and endothelial dysfunction in type II diabetes: a possible link. Diabetologia 2001;44:1155-60
15. Foresta C, Caretta N, Lana A, et al. Circulating endothelial progenitor cells in subjects with erectile dysfunction. Int J Impot Res 2005;17:288-90
16. Sullivan ME, Keoghane SR, Miller MA. Vascular risk factors and erectile dysfunction. BJU Int 2001;87:838-45
17. Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996-3002
18. Pritzker MR. The penile stress test: a window to the hearts of man? Circulation 1999;111:3711 [Abstract 3751]
19. Anderson M, Nicholson B, Louie E, Mulhall JP. An analysis of vasculogenic erectile dysfunction as a potential predictor of occult cardiac disease. J Urol 1998;159:130 [Abstract 118]
20. Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int J Impot Res 2003;15:63-71
21. Jiann BP, Yu CC, Su CC, Tsai JY. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res 2006;18:146-9
22. Blount MA, Beasley A, Zoraghi R, et al. Binding of titrated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 2004;66:144-52
23. Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802-13
24. Viagra (sildenafil citrate) [prescribing information]. New York, NY; Pfizer Inc; October, 2006
25. Levitra (vardenafil HCl) [prescribing information]. West Haven, CT; Research Triangle Park, NC; and Kenilworth, NJ; Bayer Healthcare, GlaxoSmithKline, and Schering-Plough Corporation; March, 2007
26. Cialis (tadalafil) [prescribing information]. Indianapolis, IN; Eli Lilly and Company; January, 2007
27. Gittelman M. Vardenafil extended 12 hour data abstract. J Sex Med 2006;3:28-29 [Abstract 44]
28. Eardley I, Dean J, Barnes T, et al. The sexual habits of British men and women over 40 years old. BJU Int 2004;93:563-7
29. Giuliano F, Sanchez Ramos A, Loechner Ernst D, et al. Tadalafil in men with erectile dysfunction and spinal cord injury [abstract]. Presented at: the 21st Annual EAU Congress; April 5-8, 2006; Paris, France. [Abstract 469]
30. Carson C, Shabsigh R, Segal S, et al; Trial Evaluating the Activity of Tadalafil for Erectile Dysfunction-United States (TREATED-US) Study Group. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Urology 2005;65:353-9
31. Dunn ME, Althof SE, Perelman MA. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction. Int J Impot Res 2007;19: 119-23
32. Evolving understanding of erectile dysfunction strategies for diagnosis and intervention. J Sex Med 2006;3(Suppl 1): 10-13
33. McCullough AR, Barada JH, Fawzy A, et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002;60:28-38
34. Schulman CC, Shen W, Stothard DR, Schmitt H. Integrated analysis examining first-dose success, success by dose, and maintenance of success among men taking tadalafil for erectile dysfunction. Urology 2004;64:783-8
35. Montorsi F, Hellstrom WJ, Valiquette L, et al. Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology 2004;64:1187-95
36. Valiquette L, Young JM, Moncada I, et al. Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2005;80:1291-7
37. Valiquette L, Montorsi F, Auerbach S. First-dose success with vardenafil in men with erectile dysfunction and associated comorbidities: RELY-I. Int J Clin Pract 2006;60: 1378-85
38. Valiquette L, Auerbach S, Nathan HP, et al. Vardenafil provides initial and subsequent penetration reliability in patients with a high rate of comorbidities and erectile dysfunction: the reliability-vardenafil for erectile dysfunction II (RELY-II) trial. J Sex Med 2006;3:162-3 [Abstract 154]
39. Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol 2002;53(Suppl 1):61-5S
40. Padma-Nathan H, Stecher VJ, Sweeney M, et al. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 2003;62:400-3
41. Gingell C, Sultana SR, Wulff MB, Gepi-Attee S. Duration of action of sildenafil citrate in men with erectile dysfunction. J Sex Med 2004;1:179-84
42. Carson CC, Rajfer J, Eardley I, et al. The efficacy and safety of tadalafil: an update. BJU Int 2004;93:1276-81
43. Moncada I, Damber J-E, Mirone V, et al. Sexual intercourse attempt patterns with two dosing regimens of tadalafil in men with erectile dysfunction: results from the SURE study in 14 European countries. J Sex Med 2005;2:688-74
44. Valiquette L, Montorsi F, Hellstrom WJ, et al. Penetration and maintenance of erection with vardenafil: a time-from-dosing analysis. Can J Urol 2005;12:2687-98
45. Porst H, Sharlip ID, Hatzichristou D, et al; for the Vardenafil Study Group. Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study. Eur Urol 2006;50:1086-94
46. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-6
47. Stuckey BG, Jadzinsky MN, Murphy LJ, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003;26:279-84
48. Saenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25:2159-64
49. Lewis RW, Sadovsky R, Eardley I, et al. The efficacy of tadalafil in clinical populations. J Sex Med 2005;2:517-31
50. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83
51. Ziegler D, Merfort F, Van Ahlen H, et al. Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in type 1 diabetic patients with erectile dysfunction. Diabetes 2005;54:A127 [Abstract 514-P]
52. van Ahlen H, Wahle K, Kupper W, et al. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005;2:856-64
53. Pickering TG, Shepherd AM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens 2004;17:1135-42
54. Goldstein I, Kim E, Steers WD, et al. Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. J Sex Med 2007;4:166-75
55. Goldfischer E, Eardley I, Segerson T. Vardenafil improves erectile function in men with significant comorbidities association with erectile dysfunction. J Urol 2002;167:178 [Abstract 714]
56. Young JM, Bennett C, Gilhooly P, et al. Efficacy and safety of sildenafil citrate (Viagra) in black and Hispanic American men. Urology 2002;60:39-48
57. Rashid A. The efficacy and safety of PDE5 inhibitors. Clin Cornerstone 2005;7:47-56
58. McGee HT, Egan RA, Clark WM. Visual field defect and intracerebral hemorrhage associated with use of vardenafil (Levitra). Neurology 2005;64:1095-6
59. Tomsak R. PDE5 inhibitors and permanent visual loss. Int J Impot Res 2005;17:547-9
60. US Food and Drug Administration. FDA alert for healthcare professionals (vardenafil) [online. Available from http://www. fda.gov/cder/drug/InfoSheets/ HCP/vardenafilHCP.pdf/ [Last accessed 07 August 2007]
61. McGwin G Jr, Vaphiades MS, Hall TA, Owsley C. Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction. Br J Ophthalmol 2006;90:154-7
62. Hellstrom WJG, White WB, Sprenger K, et al. Cardiovascular safety of vardenafil in patients on antihypertensive therapies and alpha-blockers: finding from analyses of 17 placebo-controlled clinical trials. J Urol 2005;173:200 [Abstract 873]
63. Auerbach SM, Gittelman M, Mazzu A, et al. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004;64:998-1003
64. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004;172(5 Pt 1):1935-40